Metharbital
From Wikipedia, the free encyclopedia
| Image:Metharbital.png | |
| Metharbital
| |
| Systematic (IUPAC) name | |
| 5,5-diethyl-1-methyl-hexahydropyrimidine-2,4,6-trione | |
| Identifiers | |
| CAS number | 50-11-3 |
| ATC code | N03AA30 |
| PubChem | 4099 |
| DrugBank | APRD00757 |
| Chemical data | |
| Formula | C9H14N2O3 |
| Mol. weight | 198.219 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Metharbital was marketed as Gemonil by Abbott Laboratories. It is a barbiturate anticonvulsant, used in the treatment of epilepsy. It has similar properties to phenobarbital.
[edit] History
- 1952 Gemonil was introduced by Abbott Laboratories.
- 1990 Abbott stopped marketing.
[edit] References
- The Treatment of Epilepsy 2nd Ed by S. D. Shorvon (Editor), David R. Fish (Editor), Emilio Perucca (Editor), W. Edwin Dodson (Editor). Published by Blackwell 2004. ISBN 0-632-06046-8
- The Medical Treatment of Epilepsy by Stanley R Resor. Published by Marcel Dekker (1991). ISBN 0-8247-8549-5.
- The Comparative Toxicogenomics Database: Metharbital

